跳至主要内容
临床试验/NCT02800551
NCT02800551已完成2 期

Dose-intensified Image-guided Fractionated Stereotactic Body Radiation Therapy for Painful Spinal Metastases Versus Conventional Radiation Therapy: a Randomised Controlled Trial (DOSIS RCT)

University of Zurich1 个研究点 分布在 1 个国家目标入组 219 人开始时间: 2016年7月8日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
入组人数
219
试验地点
1
主要终点
Pain response - improvement by ≥ 2 points on the pain Visual Analogue Scale at 6 months post-treatment at the treatment site

研究概览

简要总结

This study will compare pain (primary end-point) and local metastatic tumor control (secondary end-point) after dose-intensified image-guided fractionated stereotactic body radiation therapy (SBRT) for painful mass-type spinal metastases versus conventional radiation therapy.

详细描述

Rationale: Radiation therapy is an effective palliative treatment for painful spinal metastases. A sub-group of patients with mass-type spinal metastases, a factor associated with poor local metastasis control, require treatment optimization ensuring durable pain control and metastatic tumor control.

Proposed solution: To intensify (escalate) radiation dose using simultaneous integrated boost with image-guided hypofractionated SBRT for painful mass-type spinal metastases in a randomized controlled trial. Two experimental fractionation regimes will be tested in the study depending on presence or absence of epidural involvement. Dose intensification is expected to achieve long-term pain control and long-term palliation as well as long-term local metastatic tumor control without adding toxicity as compared to conventional fractionation regimes with conventional radiation therapy.

The study will be carried out as multinational, multicentre phase II clinical controlled trial enrolling patients with painful mass-type spinal metastases who are eligible for radiation therapy without surgery. This study additionally includes a prospective observational arm for patients not eligible for randomisation who are treated in analogy to arm A of the randomised arm.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Established histological diagnosis of a malignant primary or metastatic tumor;
  • Histologically, radiologically or scintigraphically proven spinal metastasis;
  • Pain in the affected spinal region or free of pain under pain medication;
  • Age ≥18 years old;
  • Karnofsky performance status ≥60%;
  • Written informed consent.

排除标准

  • Modified Bauer Score < 2;
  • No-mass-type metastatic lesion, defined as a 3D space-occupying lesion visible on CT and/or MR;
  • "Radiosensitive" histology of the primary tumor, e.g., lymphoma, small-cell lung cancer, multiple myeloma, germ cell tumors;
  • Progressive neurological symptoms/deficit;
  • More than 3 affected vertebrae in one target site;
  • More than 2 treatment sites;
  • Spinal Instability Neoplastic Score (SINS) 13 - 18, i.e., unstable;
  • Unable to tolerate treatment (unable to lie flat and immobilized);
  • Previous radiotherapy of the region at the level of the affected vertebrae;
  • Previous radionuclide therapy within 30 days before stereotactic body radiation therapy;
  • Previous surgery (stabilization) of the affected vertebrae;
  • Contraindications for MR scanning, e.g., pacemakers;
  • Patients with allergy to contrast agents used in computer tomography (CT) and magnetic resonance (MR) imaging or patients who cannot be premedicated to use contrast agent;
  • Pregnant or lactating women;
  • Women of child bearing potential or sexually active males not willing to use effective contraception while on treatment and 3 months after the end of treatment;
  • Mental conditions rendering the patient unable to understand the nature, scope, and possible consequences of the study;
  • Patient unlikely to comply with protocol, i.e. uncooperative attitude, inability to return for follow-up visits, and unlikely to complete the study.

研究组 & 干预措施

SBRT (Arm A)

Experimental

dose-intensified image-guided SBRT using simultaneous integrated boost:

  • in the case of no epidural involvement: 40 Gy and 20 Gy in 5 fractions to the high-dose and conventional-dose target volume, respectively.
  • In the case epidural involvement: 48.5 Gy and 30 Gy in 10 fractions to the high-dose and conventional-dose target volume, respectively.

干预措施: dose-intensified image-guided SBRT using simultaneous integrated boost (Radiation)

Conventional Radiation Therapy (Arm B)

Active Comparator

External 3-dimensional conformal radiotherapy (3D-CRT):

Homogeneous irradiation of the affected vertebra delivering either

  • 20 Gy in 5 fractions or
  • 30 Gy in 10 fractions.

干预措施: External 3-dimensional conformal radiotherapy (3D-CRT) (Radiation)

SBRT (prospective observational)

Experimental

Patients eligible for the prospective observational arm will be treated according to the investigational arm (arm A) of the randomised arm of the trial.

干预措施: dose-intensified image-guided SBRT using simultaneous integrated boost (Radiation)

结局指标

主要结局

Pain response - improvement by ≥ 2 points on the pain Visual Analogue Scale at 6 months post-treatment at the treatment site

时间窗: 6 months

次要结局

  • Overall survival(up to 2 years)
  • Local metastasis control(up to 2 years)
  • Cancer-specific survival(up to 2 years)
  • Quality-of-life (QoL)(Day 1 and last day of treatment (usually day5 if Radiotherapy is delivered in 5 fractions, and day 12 if Radiotherapy is delivered in 10 fractions); months 1, 3, 6, 9, 12, 18 and 24)
  • Epidural spinal cord compression(up to 2 years)
  • Acute and late toxicity(Acute toxicity: up to 3 months; late toxicity: from 3 months up to 24 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验